RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2017; 37(02): 135-146
DOI: 10.1055/s-0037-1601567
DOI: 10.1055/s-0037-1601567
Review Article
Genetic Forms of Parkinson's Disease
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
16. Mai 2017 (online)
Abstract
One of the greatest advances in Parkinson's disease (PD) research in the past two decades has been a better understanding of PD genetics. Of the many candidate genes investigated, the best studied include LRRK2, SNCA, VPS35, Parkin, PINK1, and DJ1. The authors review the key clinical features of these monogenic forms, as well as for the prevalent risk factor gene, GBA, including the phenotype, clinical course, and treatment response. They also outline areas for future investigation: longitudinal studies of PD's clinical course, the identification of its premotor manifestations, and its specific mechanisms of pathogenicity.
-
References
- 1 Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18 (R1): R48-R59
- 2 Wszolek ZK, Pfeiffer B, Fulgham JR , et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995; 45 (3 Pt 1): 502-505
- 3 Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51 (3) 296-301
- 4 Zimprich A, Biskup S, Leitner P , et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44 (4) 601-607
- 5 Paisán-Ruíz C, Jain S, Evans EW , et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44 (4) 595-600
- 6 Rosenbusch KE, Kortholt A. Activation mechanism of LRRK2 and its cellular functions in Parkinson's disease. Parkinsons Dis 2016; 2016: 7351985
- 7 West AB, Cookson MR. Identification of bona-fide LRRK2 kinase substrates. Mov Disord 2016; 31 (8) 1140-1141
- 8 Pankratz N, Pauciulo MW, Elsaesser VE , et al; Parkinson Study Group-PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson's disease. Mov Disord 2006; 21 (12) 2257-2260
- 9 Gorostidi A, Ruiz-Martínez J, Lopez de Munain A, Alzualde A, Martí Massó JF. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009; 10 (2) 157-159
- 10 Funayama M, Hasegawa K, Ohta E , et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005; 57 (6) 918-921
- 11 Lu CS, Simons EJ, Wu-Chou YH , et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord 2005; 11 (8) 521-522
- 12 Funayama M, Li Y, Tomiyama H , et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007; 18 (3) 273-275
- 13 Kim JM, Lee JY, Kim HJ , et al. The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. Parkinsonism Relat Disord 2010; 16 (2) 85-88
- 14 Di Fonzo A, Wu-Chou YH, Lu CS , et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006; 7 (3) 133-138
- 15 Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 2006; 6: 47
- 16 Chan DK, Ng PW, Mok V , et al. LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients. J Neural Transm (Vienna) 2008; 115 (9) 1275-1277
- 17 An XK, Peng R, Li T , et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Eur J Neurol 2008; 15 (3) 301-305
- 18 Marras C, Alcalay RN, Caspell-Garcia C , et al; LRRK2 Cohort Consortium. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease. Mov Disord 2016; 31 (8) 1192-1202
- 19 Aasly JO, Toft M, Fernandez-Mata I , et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005; 57 (5) 762-765
- 20 Di Fonzo A, Rohé CF, Ferreira J , et al; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365 (9457): 412-415
- 21 Healy DG, Falchi M, O'Sullivan SS , et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7 (7) 583-590
- 22 Tan EK, Shen H, Tan LC , et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005; 384 (3) 327-329
- 23 Marder K, Wang Y, Alcalay RN , et al; LRRK2 Ashkenazi Jewish Consortium. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 2015; 85 (1) 89-95
- 24 Alcalay RN, Mejia-Santana H, Tang MX , et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009; 66 (12) 1517-1522
- 25 Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. Mov Disord 2015; 30 (2) 253-258
- 26 Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005; 57 (6) 933-934
- 27 Gilks WP, Abou-Sleiman PM, Gandhi S , et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365 (9457): 415-416
- 28 Ben Sassi S, Nabli F, Hentati E , et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (3) 243-246
- 29 Alcalay RN, Mejia-Santana H, Mirelman A , et al; LRRK2 Ashkenazi Jewish Consortium. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (2) 106-110
- 30 Marras C, Schüle B, Munhoz RP , et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011; 77 (4) 325-333
- 31 Saunders-Pullman R, Stanley K, San Luciano M , et al. Gender differences in the risk of familial parkinsonism: beyond LRRK2?. Neurosci Lett 2011; 496 (2) 125-128
- 32 Saunders-Pullman R, Mirelman A, Wang C , et al. Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?. Ann Clin Transl Neurol 2014; 1 (9) 670-678
- 33 Saunders-Pullman R, Alcalay RN, Mirelman A , et al; AJ LRRK2 Consortium. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Mov Disord 2015; 30 (13) 1834-1839
- 34 Saunders-Pullman R, Barrett MJ, Stanley KM , et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord 2010; 25 (15) 2536-2541
- 35 Inzelberg R, Cohen OS, Aharon-Peretz J , et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012; 78 (11) 781-786
- 36 Saunders-Pullman R, Stanley K, Wang C , et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 2011; 77 (4) 319-324
- 37 Mirelman A, Alcalay RN, Saunders-Pullman R , et al; LRRK2 AJ consortium. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Mov Disord 2015; 30 (7) 981-986
- 38 Mirelman A, Bernad-Elazari H, Thaler A , et al. Arm swing as a potential new prodromal marker of Parkinson's disease. Mov Disord 2016; 31 (10) 1527-1534
- 39 Shanker V, Groves M, Heiman G , et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov Disord 2011; 26 (10) 1875-1880
- 40 Poulopoulos M, Cortes E, Vonsattel JP , et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci 2012; 47 (1) 139-143
- 41 Kalia LV, Lang AE, Hazrati LN , et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015; 72 (1) 100-105
- 42 Polymeropoulos MH, Higgins JJ, Golbe LI , et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996; 274 (5290): 1197-1199
- 43 Polymeropoulos MH, Lavedan C, Leroy E , et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276 (5321): 2045-2047
- 44 Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998; 50 (2) 513-514
- 45 Scott WK, Yamaoka LH, Stajich JM , et al. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 1999; 2 (3) 191-192
- 46 Zarranz JJ, Alegre J, Gómez-Esteban JC , et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55 (2) 164-173
- 47 Krüger R, Kuhn W, Müller T , et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18 (2) 106-108
- 48 Proukakis C, Dudzik CG, Brier T , et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013; 80 (11) 1062-1064
- 49 Lesage S, Anheim M, Letournel F , et al; French Parkinson's Disease Genetics Study Group. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73 (4) 459-471
- 50 Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013; 28 (6) 697-701
- 51 Chartier-Harlin MC, Kachergus J, Roumier C , et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364 (9440): 1167-1169
- 52 Papadimitriou D, Antonelou R, Miligkos M , et al. Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study. Mov Disord 2016; 31 (8) 1226-1230
- 53 Singleton AB, Farrer M, Johnson J , et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302 (5646): 841
- 54 Nishioka K, Ross OA, Ishii K , et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 2009; 24 (12) 1811-1819
- 55 Ahn TB, Kim SY, Kim JY , et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70 (1) 43-49
- 56 Ibáñez P, Bonnet AM, Débarges B , et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364 (9440): 1169-1171
- 57 Vilariño-Güell C, Wider C, Ross OA , et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89 (1) 162-167
- 58 Zimprich A, Benet-Pagès A, Struhal W , et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89 (1) 168-175
- 59 Guella I, Soldà G, Cilia R , et al. The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Mov Disord 2012; 27 (6) 800-801
- 60 Lesage S, Condroyer C, Klebe S , et al; French Parkinson's Disease Genetics Study Group. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 2012; 78 (18) 1449-1450
- 61 Ando M, Funayama M, Li Y , et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord 2012; 27 (11) 1413-1417
- 62 Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996; 47 (1) 160-166
- 63 Matsumine H, Saito M, Shimoda-Matsubayashi S , et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60 (3) 588-596
- 64 Kitada T, Asakawa S, Hattori N , et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392 (6676): 605-608
- 65 Hattori N, Kitada T, Matsumine H , et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 1998; 44 (6) 935-941
- 66 Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin gene mutation in a Korean woman. Arch Neurol 2001; 58 (6) 988-989
- 67 Lücking CB, Abbas N, Dürr A , et al; The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. Lancet 1998; 352 (9137): 1355-1356
- 68 Hedrich K, Marder K, Harris J , et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 2002; 58 (8) 1239-1246
- 69 Marder KS, Tang MX, Mejia-Santana H , et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol 2010; 67 (6) 731-738
- 70 Li X, Gehring K. Structural studies of parkin and sacsin: mitochondrial dynamics in neurodegenerative diseases. Mov Disord 2015; 30 (12) 1610-1619
- 71 Rub C, Wilkening A, Voos W. Mitochondrial quality control by the Pink1/Parkin system. Cell Tissue Res 2017; 367 (1) 111-123
- 72 Kilarski LL, Pearson JP, Newsway V , et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord 2012; 27 (12) 1522-1529
- 73 Hedrich K, Eskelson C, Wilmot B , et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 2004; 19 (10) 1146-1157
- 74 Klein C, Schumacher K, Jacobs H , et al. Association studies of Parkinson's disease and parkin polymorphisms. Ann Neurol 2000; 48 (1) 126-127
- 75 Deng H, Le WD, Hunter CB , et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006; 63 (2) 273-277
- 76 Kann M, Hedrich K, Vieregge P , et al. The parkin gene is not involved in late-onset Parkinson's disease. Neurology 2002; 58 (5) 835 , author reply 835
- 77 Oliveira SA, Scott WK, Martin ER , et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 2003; 53 (5) 624-629
- 78 Klein C, Hedrich K, Wellenbrock C , et al. Frequency of parkin mutations in late-onset Parkinson's disease. Ann Neurol 2003; 54 (3) 415-416 , author reply 416–417
- 79 Khan NL, Brooks DJ, Pavese N , et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002; 125 (Pt 10): 2248-2256
- 80 Lohmann E, Thobois S, Lesage S , et al; French Parkinson's Disease Genetics Study Group. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009; 72 (2) 110-116
- 81 Caccappolo E, Alcalay RN, Mejia-Santana H , et al. Neuropsychological profile of Parkin mutation carriers with and without Parkinson disease: the CORE-PD Study. J Int Neuropsychol Soc 2011; 17 (1) 91-100
- 82 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 2014; 71 (1) 62-67
- 83 Khan NL, Katzenschlager R, Watt H , et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004; 62 (7) 1224-1226
- 84 Alcalay RN, Siderowf A, Ottman R , et al. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology 2011; 76 (4) 319-326
- 85 Morgante F, Fasano A, Ginevrino M , et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. Neurology 2016; 87 (14) 1436-1441
- 86 Cesari R, Martin ES, Calin GA , et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003; 100 (10) 5956-5961
- 87 Fujiwara M, Marusawa H, Wang HQ , et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008; 27 (46) 6002-6011
- 88 Poulogiannis G, McIntyre RE, Dimitriadi M , et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 2010; 107 (34) 15145-15150
- 89 Veeriah S, Taylor BS, Meng S , et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010; 42 (1) 77-82
- 90 Alcalay RN, Clark LN, Marder KS, Bradley WE. Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer 2012; 51 (12) 1109-1113
- 91 Kay DM, Moran D, Moses L , et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007; 61 (1) 47-54
- 92 Kay DM, Stevens CF, Hamza TH , et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75 (13) 1189-1194
- 93 Pankratz N, Kissell DK, Pauciulo MW , et al; Parkinson Study Group-PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009; 73 (4) 279-286
- 94 Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A. High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol 2005; 252 (2) 208-211
- 95 Moro E, Volkmann J, König IR , et al. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 2008; 70 (14) 1186-1191
- 96 Angeli A, Mencacci NE, Duran R , et al. Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation. Mov Disord 2013; 28 (10) 1370-1375
- 97 Pramstaller PP, Schlossmacher MG, Jacques TS , et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005; 58 (3) 411-422
- 98 Doherty KM, Silveira-Moriyama L, Parkkinen L , et al. Parkin disease: a clinicopathologic entity?. JAMA Neurol 2013; 70 (5) 571-579
- 99 Valente EM, Bentivoglio AR, Dixon PH , et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001; 68 (4) 895-900
- 100 Valente EM, Abou-Sleiman PM, Caputo V , et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304 (5674): 1158-1160
- 101 Valente EM, Salvi S, Ialongo T , et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56 (3) 336-341
- 102 Rogaeva E, Johnson J, Lang AE , et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61 (12) 1898-1904
- 103 Ibáñez P, Lesage S, Lohmann E , et al; French Parkinson's Disease Genetics Study Group. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006; 129 (Pt 3): 686-694
- 104 Hatano Y, Sato K, Elibol B , et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004; 63 (8) 1482-1485
- 105 Bonifati V, Rohé CF, Breedveld GJ , et al; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65 (1) 87-95
- 106 Truban D, Hou X, Caulfield TR, Fiesel FC, Springer W. PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson's disease pathobiology?. J Parkinsons Dis 2017; 7 (1) 13-29
- 107 Bentivoglio AR, Cortelli P, Valente EM , et al. Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord 2001; 16 (6) 999-1006
- 108 Ephraty L, Porat O, Israeli D , et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007; 22 (4) 566-569
- 109 Ferraris A, Ialongo T, Passali GC , et al. Olfactory dysfunction in parkinsonism caused by PINK1 mutations. Mov Disord 2009; 24 (16) 2350-2357
- 110 Abou-Sleiman PM, Muqit MM, McDonald NQ , et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 2006; 60 (4) 414-419
- 111 Kasten M, Weichert C, Lohmann K, Klein C. Clinical and demographic characteristics of PINK1 mutation carriers--a meta-analysis. Mov Disord 2010; 25 (7) 952-954
- 112 Samaranch L, Lorenzo-Betancor O, Arbelo JM , et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010; 133 (Pt 4): 1128-1142
- 113 Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 2016; 86 (23) 2212-2213
- 114 van Duijn CM, Dekker MC, Bonifati V , et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69 (3) 629-634
- 115 Bonifati V, Rizzu P, van Baren MJ , et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299 (5604): 256-259
- 116 Sironi F, Primignani P, Ricca S , et al. DJ1 analysis in a large cohort of Italian early onset Parkinson disease patients. Neurosci Lett 2013; 557 (Pt B): 165-170
- 117 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010; 67 (9) 1116-1122
- 118 Maraganore DM, Wilkes K, Lesnick TG , et al. A limited role for DJ1 in Parkinson disease susceptibility. Neurology 2004; 63 (3) 550-553
- 119 Neudorfer O, Giladi N, Elstein D , et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89 (9) 691-694
- 120 Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005; 65 (9) 1460-1461
- 121 Beavan MS, Schapira AH. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 2013; 45 (8) 511-521
- 122 Alcalay RN, Levy OA, Waters CC , et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015; 138 (Pt 9): 2648-2658
- 123 Huang CL, Wu-Chou YH, Lai SC , et al. Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan. Eur J Neurol 2011; 18 (10) 1227-1232
- 124 Wu YR, Chen CM, Chao CY , et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007; 78 (9) 977-979
- 125 Lesage S, Anheim M, Condroyer C , et al; French Parkinson's Disease Genetics Study Group. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011; 20 (1) 202-210
- 126 Neumann J, Bras J, Deas E , et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132 (Pt 7): 1783-1794
- 127 Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351 (19) 1972-1977
- 128 Sidransky E, Nalls MA, Aasly JO , et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361 (17) 1651-1661
- 129 Gan-Or Z, Giladi N, Rozovski U , et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008; 70 (24) 2277-2283
- 130 Anheim M, Elbaz A, Lesage S , et al; French Parkinson Disease Genetic Group. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78 (6) 417-420
- 131 Alcalay RN, Dinur T, Quinn T , et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014; 71 (6) 752-757
- 132 Gan-Or Z, Amshalom I, Kilarski LL , et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015; 84 (9) 880-887
- 133 Brockmann K, Srulijes K, Pflederer S , et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015; 30 (3) 407-411
- 134 Oeda T, Umemura A, Mori Y , et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging 2015; 36 (12) 3306-3313
- 135 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78 (18) 1434-1440
- 136 Brockmann K, Srulijes K, Hauser AK , et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77 (3) 276-280
- 137 Gan-Or Z, Mirelman A, Postuma RB , et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann Clin Transl Neurol 2015; 2 (9) 941-945
- 138 Cilia R, Tunesi S, Marotta G , et al. Survival and dementia in GBA-associated Parkinson's disease: the mutation matters. Ann Neurol 2016; 80 (5) 662-673
- 139 Thaler A, Gurevich T, Bar Shira A , et al. A “dose” effect of mutations in the GBA gene on Parkinson's disease phenotype. Parkinsonism Relat Disord 2016; S1353-8020(16)30495-3
- 140 Clark LN, Kartsaklis LA, Wolf Gilbert R , et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66 (5) 578-583
- 141 Parkkinen L, Neumann J, O'Sullivan SS , et al. Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Mol Genet Metab 2011; 103 (4) 410-412
- 142 Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120 (5) 641-649
- 143 Funayama M, Ohe K, Amo T , et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol 2015; 14 (3) 274-282
- 144 Foo JN, Liu J, Tan EK. CHCHD2 and Parkinson's disease. Lancet Neurol 2015; 14 (7) 681-682
- 145 Koschmidder E, Weissbach A, Brüggemann N, Kasten M, Klein C, Lohmann K. A nonsense mutation in CHCHD2 in a patient with Parkinson disease. Neurology 2016; 86 (6) 577-579
- 146 Gagliardi M, Iannello G, Colica C, Annesi G, Quattrone A. Analysis of CHCHD2 gene in familial Parkinson's disease from Calabria. Neurobiol Aging 2017; 50: 169.e5-169.e6
- 147 Tejera-Parrado C, Jesús S, Huertas-Fernández I , et al. Genetic analysis of CHCHD2 in a southern Spanish population. Neurobiol Aging 2017; 50: 169.e1-169.e2
- 148 Fan TS, Lin HI, Lin CH, Wu RM. Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiol Aging 2016; 38: 218.e1-218.e2
- 149 Li NN, Wang L, Tan EK , et al. Genetic analysis of CHCHD2 gene in Chinese Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2016; 171 (8) 1148-1152
- 150 Yang X, Zhao Q, An R , et al. Mutational scanning of the CHCHD2 gene in Han Chinese patients with Parkinson's disease and meta-analysis of the literature. Parkinsonism Relat Disord 2016; 29: 42-46
- 151 Deng HX, Shi Y, Yang Y , et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet 2016; 48 (7) 733-739
- 152 Yan W, Tang B, Zhou X , et al. TMEM230 mutation analysis in Parkinson's disease in a Chinese population. Neurobiol Aging 2017; 49: 219.e1-219.e3
- 153 Giri A, Mok KY, Jansen I , et al; International Parkinson's Disease Consortium (IPDGC). Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiol Aging 2017; 50: 167.e11-167.e13
- 154 Sudhaman S, Muthane UB, Behari M, Govindappa ST, Juyal RC, Thelma BK. Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson's disease with non-motor phenotypes. J Med Genet 2016; 53 (8) 559-566
- 155 Gan-Or Z, Ozelius LJ, Bar-Shira A , et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 2013; 80 (17) 1606-1610
- 156 Foo JN, Liany H, Bei JX , et al. Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease. Neurobiol Aging 2013; 34 (12) 2890.e13-2890.e15
- 157 Dagan E, Adir V, Schlesinger I , et al. SMPD1 mutations and Parkinson disease. Parkinsonism Relat Disord 2015; 21 (10) 1296-1297
- 158 Gan-Or Z, Orr-Urtreger A, Alcalay RN, Bressman S, Giladi N, Rouleau GA. The emerging role of SMPD1 mutations in Parkinson's disease: implications for future studies. Parkinsonism Relat Disord 2015; 21 (10) 1294-1295
- 159 Vilariño-Güell C, Rajput A, Milnerwood AJ , et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 2014; 23 (7) 1794-1801
- 160 Gibb WR, Narabayashi H, Yokochi M, Iizuka R, Lees AJ. New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 1991; 41 (6) 820-822
- 161 Guella I, Sherman HE, Appel-Cresswell S, Rajput A, Rajput AH, Farrer MJ. Parkinsonism in GTP cyclohydrolase 1 mutation carriers. Brain 2015; 138 (Pt 5): e349
- 162 Mok KY, Sheerin U, Simón-Sánchez J , et al; International Parkinson's Disease Genomics Consortium (IPDGC). Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurol 2016; 15 (6) 585-596
- 163 Butcher NJ, Kiehl TR, Hazrati LN , et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 2013; 70 (11) 1359-1366
- 164 Köroğlu Ç, Baysal L, Cetinkaya M, Karasoy H, Tolun A. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 2013; 19 (3) 320-324
- 165 Edvardson S, Cinnamon Y, Ta-Shma A , et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 2012; 7 (5) e36458
- 166 Elsayed LE, Drouet V, Usenko T , et al. A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease. Ann Neurol 2016; 79 (2) 335-337
- 167 Olgiati S, Quadri M, Fang M , et al; International Parkinsonism Genetics Network. DNAJC6 mutations associated with early-onset Parkinson's disease. Ann Neurol 2016; 79 (2) 244-256
- 168 Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994; 89 (5) 347-352
- 169 Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov Disord 2015; 30 (6) 770-779
- 170 Lesage S, Drouet V, Majounie E , et al; French Parkinson's Disease Genetics Study (PDG); International Parkinson's Disease Genomics Consortium (IPDGC). Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. Am J Hum Genet 2016; 98 (3) 500-513
- 171 Quadri M, Fang M, Picillo M , et al; International Parkinsonism Genetics Network. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat 2013; 34 (9) 1208-1215
- 172 Di Fonzo A, Dekker MC, Montagna P , et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009; 72 (3) 240-245
- 173 Lohmann E, Coquel AS, Honoré A , et al. A new F-box protein 7 gene mutation causing typical Parkinson's disease. Mov Disord 2015; 30 (8) 1130-1133
- 174 Malaguti MC, Melzi V, Di Giacopo R , et al. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism. Parkinsonism Relat Disord 2015; 21 (3) 337-339
- 175 Wilson GR, Sim JC, McLean C , et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am J Hum Genet 2014; 95 (6) 729-735
- 176 Mata IF, Jang Y, Kim CH , et al. The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Mol Neurodegener 2015; 10: 50
- 177 Lesage S, Bras J, Cormier-Dequaire F , et al; French Parkinson's Disease Genetics Study Group (PDG) and the International Parkinson's Disease Genomics Consortium (IPDGC). Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease. Neurol Genet 2015; 1 (1) e9